奥希替尼序贯治疗表皮生长因子受体突变阳性非小细胞肺癌患者的研究：GioTag 研究的最终分析。
Sequential afatinib and osimertinib in patients with mutation-positive non-small-cell lung cancer: final analysis of the GioTag study.
机构信息
Department of Respiratory & Critical Care Medicine, Karl Landsteiner Institute of Lung Research & Pulmonary Oncology, Krankenhaus Nord, 3500 Vienna, Austria.
Thoracic Medical Oncology, Istituto Nazionale Tumori, "Fondazione G. Pascale"-IRCCS, 80131 Napoli, Italy.
出版信息
Future Oncol. 2020 Dec;16(34):2799-2808. doi: 10.2217/fon-2020-0740. Epub 2020 Aug 28.
Final overall survival (OS) and time on treatment analysis of patients with mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory. Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7-29.9). Median OS was 37.6 months (90% CI: 35.5-41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively. In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with mutation-positive NSCLC, especially in Del19-positive patients and Asian patients. NCT03370770 (ClinicalTrials.gov).
接受序贯阿法替尼和奥希替尼治疗的 突变阳性非小细胞肺癌（NSCLC）患者的最终总生存（OS）和治疗时间分析。患者（n=203）在一线阿法替尼治疗后出现 T790M 阳性疾病，并在数据录入前至少 10 个月开始奥希替尼治疗。主要结局是治疗时间；OS 分析是探索性的。阿法替尼和奥希替尼的中位治疗时间为 27.7 个月（90%CI：26.7-29.9）。中位 OS 为 37.6 个月（90%CI：35.5-41.3）；Del19 阳性患者和亚洲患者的中位 OS 分别为 41.6 个月和 44.8 个月。在真实世界的临床实践中，序贯阿法替尼和奥希替尼治疗 突变阳性 NSCLC 患者的结局令人鼓舞，尤其是 Del19 阳性患者和亚洲患者。NCT03370770（ClinicalTrials.gov）。
Zotero 插件